Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Claire Mitchell

Showing results (61-70 of 69) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 69 results.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 3, 2024
Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition geneRobert D Morgan, George J Burghel, Nicola Flaum, et al.
Nature Communications|April 17, 2024
A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primaryAlicia-Marie Conway, Simon P Pearce, Alexandra Clipson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 9, 2024
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trialAlexander D Murphy, Catharine Porter, Ann White, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 29, 2025
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trialAlexander D Murphy, Catharine Porter, Ann White, et al.
Journal of Clinical Pathology|June 23, 2022
Predicting the likelihood of a <i>BRCA1/2</i> pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancerRobert D Morgan, George J Burghel, Nicola Flaum, et al.
British Journal of Cancer|November 16, 2024
Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancerRobert D Morgan, Xin Wang, Bethany M Barnes, et al.
The Journal of Cell Biology|June 9, 2025
Metabolic adaptations of micrometastases alter EV production to generate invasive microenvironmentsMichalis Gounis, America V Campos, Engy Shokry, et al.
The Bone & Joint Journal|December 2, 2024
The National Joint Registry Data Quality Audit of elbow arthroplastyZaid Hamoodi, Joanne Shapiro, Adrian Sayers, et al.
Autophagy|February 26, 2021
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)<sup>1</sup>Daniel J Klionsky, Amal Kamal Abdel-Aziz, Sara Abdelfatah, et al.
Pageof 7

Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Genetics in Medicine : Official Journal of the American College of Medical Genetics|August 3, 2024
Extended panel testing in ovarian cancer reveals BRIP1 as the third most important predisposition geneRobert D Morgan, George J Burghel, Nicola Flaum, et al.
Nature Communications|April 17, 2024
A cfDNA methylation-based tissue-of-origin classifier for cancers of unknown primaryAlicia-Marie Conway, Simon P Pearce, Alexandra Clipson, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 9, 2024
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trialAlexander D Murphy, Catharine Porter, Ann White, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|March 29, 2025
Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trialAlexander D Murphy, Catharine Porter, Ann White, et al.
Journal of Clinical Pathology|June 23, 2022
Predicting the likelihood of a <i>BRCA1/2</i> pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancerRobert D Morgan, George J Burghel, Nicola Flaum, et al.
British Journal of Cancer|November 16, 2024
Germline BRCA1/2 status and chemotherapy response score in high-grade serous ovarian cancerRobert D Morgan, Xin Wang, Bethany M Barnes, et al.
The Journal of Cell Biology|June 9, 2025
Metabolic adaptations of micrometastases alter EV production to generate invasive microenvironmentsMichalis Gounis, America V Campos, Engy Shokry, et al.
The Bone & Joint Journal|December 2, 2024
The National Joint Registry Data Quality Audit of elbow arthroplastyZaid Hamoodi, Joanne Shapiro, Adrian Sayers, et al.
Autophagy|February 26, 2021
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)<sup>1</sup>Daniel J Klionsky, Amal Kamal Abdel-Aziz, Sara Abdelfatah, et al.
Pageof 7